Skip to main
MRK
MRK logo

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 32 analyst ratings
Buy
Strong Buy 31%
Buy 28%
Hold 38%
Sell 0%
Strong Sell 3%

Bulls say

Merck & Co. is anticipated to experience robust growth beginning in the second half of 2025 and extending into 2026 and 2027, driven by a diverse portfolio that includes successful vaccines and innovative treatments in oncology and infectious diseases. The company is strategically positioned to capture significant market share with its Capvaxive pneumococcal vaccine and RSV antibody products, while its transition to Keytruda’s subcutaneous formulation may further bolster revenues post-loss of exclusivity. Additionally, anticipated launches of clesrovimab and advancements in ongoing trials, such as MK-8527 for HIV prevention, underscore Merck's ongoing commitment to expanding its market presence and product offerings.

Bears say

Merck & Co faces significant challenges impacting its stock outlook, primarily due to anticipated revenue declines from its Keytruda immunotherapy treatment following the loss of exclusivity and increased competition from biosimilars, with projections estimating a revenue reduction of up to 58%. Additionally, performance issues with other products, such as Winrevair, which underperformed relative to both management expectations and consensus estimates, raise concerns about the company's ability to maintain growth across its portfolio. Overall, these factors contribute to a lowered valuation and heightened uncertainty regarding Merck's future revenue streams, particularly in light of regulatory pressures from initiatives like the Medicare IRA price negotiations.

Merck (MRK) has been analyzed by 32 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 28% recommend Buy, 38% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 32 analysts, Merck (MRK) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $110.34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $110.34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.